On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridaySep 23, 2016 1:27 pm

Cowen Group, Inc.’s (COWN) Prime Services Division Wins another Hedgeweek Award

Cowen Group (NASDAQ: COWN) this morning announced that its Cowen Prime Services LLC division was named Best North American Prime Broker at the 2016 Hedgeweek USA Awards. The award is based on a peer review system with the top performer of each category selected by Hedgeweek’s audience of institutional and high net worth investors, hedge fund managers and other industry professionals at fund administrators, prime brokers, law firms, custodians and advisers. This the second consecutive year, and the third in four, that Cowen Prime has received this award. Additionally, Cowen Prime earlier this year was named “Best Global Prime Broker”…

Continue Reading

FridaySep 23, 2016 1:24 pm

Aehr Test Systems (AEHR) Announces Private Placement, Posts Preliminary Q1 2017 Financial Results

Aehr Test Systems (NASDAQ: AEHR) has signed a definitive purchase agreement for the sale of approximately $5.9 million in shares of its common stock (priced at $2.15 per share) in a private placement transaction with certain institutional and accredited investors. The supplier of semiconductor test and burn-in equipment plans to use the net proceeds for working capital and general corporate purposes. Aehr also announced preliminary financial results for Q1 of fiscal 2017, expecting a GAAP net loss between $800,000 and $900,000 on revenue of $5.3 million, compared to a net loss of $3.1 million on revenue of $1.6 million in Q4…

Continue Reading

FridaySep 23, 2016 1:22 pm

BioLineRx (BLRX) In-Licenses Novel Treatment for Liver Failure Conditions

BioLineRx Ltd. (NASDAQ/TASE: BLRX) this morning said it has entered into an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, regarding the in-licensing of BL-1220 for the treatment of liver pathologies. BL-1220 marks BioLineRx’s second project in-licensed under its collaboration with Novartis Pharma AG (NYSE: NVS) for the screening and development of novel drug candidates.  "In August this year, we in-licensed the first compound under our multi-year strategic partnership with Novartis … Today, we are pleased to announce the second compound under the Novartis collaboration…

Continue Reading

FridaySep 23, 2016 1:19 pm

Laguna Blends, Inc. (LAG) (LAGBF) (LB6A.F) Joins Canadian Securities Exchange Composite Index

Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) this morning announced its inclusion to the CSE Composite index, reflecting the network marketing company’s aggressive expansion strategy. "Inclusion in the CSE Composite index is another indicator Laguna continues to deliver shareholder value through its strategic growth strategy. Laguna has positioned itself to be a dominant player in the distribution and marketing of unique hemp and CBD related products around the world," Bryan Loree, CFO of Laguna Blends, stated in the news release. Laguna Blends uses a network of independent affiliates to market its hemp-based functional beverages, and is exclusively licensed…

Continue Reading

ThursdaySep 22, 2016 2:09 pm

Terra Tech Corp.’s (TRTC) Edible Garden Begins Shipping Herb Line to Latest Customer

Terra Tech (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, this morning announced that its Edible Garden subsidiary has commenced shipping of its line of 4-inch potted living herbs to nationwide supermarket chain Wegmans Food Markets, Inc. Edible Garden is a retail seller of locally grown hydroponic produce, herbs and floral products. Its living potted herbs are USDA-certified organic and without contaminants, pesticides and GMOs. The company says that since Q2 2016 it has more than tripled production of its herb line in response to supermarket demand and increasing popularity among consumers. “As a result of the popularity of this…

Continue Reading

ThursdaySep 22, 2016 2:08 pm

New Jersey Mining Company (NJMC) Discovers New Footwall Vein, Updates on Golden Chest Mine Project

Idaho-based New Jersey Mining Company (OTCQB: NJMC) this morning reported its discovery of a new footwall vein (the “Stevens Vein”). Pit excavation revealed three veins in the pit area: a hanging wall vein thought to be the Jumbo vein, the Idaho vein, and the Stevens Vein. On the 1096 bench, trench sampling has shown the Stevens Vein and the Idaho Vein to be at least three meters wide with a grade of 15.2 grams per tonne (gpt) gold, and approximately two meters (true thickness) with a grade of 4.0 gpt gold, respectively. The company also provided an update on open…

Continue Reading

ThursdaySep 22, 2016 2:03 pm

Antares Pharma, Inc. (ATRS) Reports Safety Data from QuickShot Testosterone Clinical Program

Antares Pharma (NASDAQ: ATRS) today announced 26-week safety data from the phase 3 study of QuickShot® Testosterone (QST) administered subcutaneously once each week to adult males with hypogonadism.  The study, QST-15-005, showed that the most common adverse reactions (incidence ≥5%) were increased hematocrit, upper respiratory tract infection and injection site ecchymosis.  The company reports four patients with treatment emergent serious adverse events (SAEs), which included one patient with transient visual impairment determined not to be drug related; one patient with appendicitis that was not drug related; one patient with deep vein thrombosis (DVT), which the investigator attributed DVT as possibly…

Continue Reading

ThursdaySep 22, 2016 1:59 pm

Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate

At the World Parkinson Congress 2016 in Portland earlier today, Anavex Life Sciences (NASDAQ: AVXL) presented preclinical data in a poster titled “Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease.” Initial data demonstrated that the company’s ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson’s disease. The company reports “significant” improvements across the board, including behavioral, histopathological, and neuroinflammatory endpoints. “This initial data is encouraging, and together with already available clinical safety and tolerability data on ANAVEX 2-73, might accelerate the exploration of ANAVEX…

Continue Reading

ThursdaySep 22, 2016 1:55 pm

MagneGas Corporation (MNGA) Hits Corporate Milestone with Construction of Gasification System

MagneGas (NASDAQ: MNGA) this morning announced that it has completed construction of the Plasma-Arc Gasification system – a move company CEO Ermanno Santilli calls “the single most important event of the year.” Under the previously announced “Gasifier Agreement,” Green Arc Supply, LLC is contracted to purchase the system and thus far has paid a total of $583,750 toward construction of the system. Upon final payment of $191,500, expected in the next 30 days pending factory acceptance, Green Arc will have exclusive distribution rights to MagneGas2® for certain regions of Louisiana and Texas, as well as non-exclusive distribution rights in remaining…

Continue Reading

WednesdaySep 21, 2016 2:02 pm

Peregrine Pharmaceuticals, Inc. (PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology

Peregrine Pharmaceuticals (NASDAQ: PPHM, PPHMP) reports that it will present top-line data from the phase 3 SUNRISE trial of its bavituximab cancer treatment as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The company will present data showing that a biomarker in the SUNRISE trial correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217